Hanmi Pharmaceutical reported a 116.9% increase in operating profit for the second quarter, driven by global technology transfer achievements and growth in its domestic pharmaceutical business.
On July 28, Hanmi announced its preliminary consolidated results for Q2 2026, showing sales of 467.2 billion won and operating profit of 131.1 billion won. Compared to the same period last year, sales increased by 29.3%, and operating profit rose by 116.9%. The company recorded a net profit of 84.1 billion won for the quarter, a 95.5% increase. It invested 60.3 billion won, or 12.9% of sales, in research and development (R&D).
For the first half of the year, cumulative consolidated sales reached 860.2 billion won, a 14.4% increase from the same period last year, while operating profit rose by 54.6% to 184.7 billion won.
Hanmi stated, "The solid growth of key products like Rosuzet and the expansion of co-marketing with global pharmaceutical companies contributed to the increase in sales. The recognition of the technology transfer contract fee for sonepaglutide from Eli Lilly also played a significant role in improving our performance. We expect to achieve our highest sales figures since our founding this year."
According to Ubiest, the company recorded 561.6 billion won in external prescription sales for the first half of the year, maintaining its position as the top company in South Korea for external prescription sales for eight consecutive years since 2018.
Sales of the combination drug Rosuzet for treating dyslipidemia reached 61.6 billion won in Q2, a 10.1% increase from the previous year. The antihypertensive product line, Amlozartan Family, generated 37 billion won, while the gastroesophageal reflux disease product line, Esomezol Family, brought in 14.6 billion won.
Hanmi's Chinese subsidiary, Beijing Hanmi Pharmaceutical, reported sales of 60.7 billion won in Q2. Due to seasonal off-peak periods and the impact of China's centralized purchasing system, both sales and operating profit decreased compared to the same period last year. The company plans to secure new growth engines through the development of non-targeted items and new drugs.
Hanmi Precision Chemical, a subsidiary specializing in active pharmaceutical ingredients (APIs), recorded sales of 24 billion won in Q2, a 4.4% increase from the previous year. The increase in exports of APIs to Japan and the expansion of high-margin contract development and manufacturing (CDMO) orders contributed to a 76.7% rise in operating profit compared to the same period last year.
Hanmi is strengthening its revenue structure centered on self-developed products while expanding strategic partnerships with domestic and international pharmaceutical companies to build a sustainable growth foundation.
In the R&D sector, the company is operating over 30 innovative drug pipelines focused on obesity and metabolism, rare diseases, and oncology, enhancing its global technological competitiveness through a differentiated strategy incorporating new modalities.
The market anticipates that the upcoming launch of an obesity treatment drug at the end of the year will be a turning point. Hanmi is preparing for the launch of the glucagon-like peptide-1 (GLP-1) obesity drug, Epeglanatide, in Q4.
The next-generation obesity treatment triple-action drug, HM15275, is in Phase 2 clinical trials in the U.S., while the muscle-gaining obesity treatment drug, HM17321, has entered Phase 1 clinical trials in the U.S.
Hanmi CEO Hwang Sang-yeon stated, "We will continue to enhance corporate value and create new opportunities for growth through responsible management and continuous innovation."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.